Lineage Cell Therapeutics (LCTX): Applying Cell Therapy to Areas of Unmet Medical Need

Time: 9:00 am
day: Day Two


  • Examine OpRegen: An RPE transplant therapy in a Phase 1/2a trial for the treatment of dry-AMD with geographic atrophy
  • Explore OPC1: An oligodendrocyte progenitor therapy for acute spinal cord injuries with Orphan and RMAT designations; phase 1 completed
  • Discuss VAC2: An allogeneic cancer immunotherapy of antigenpresenting dendritic cells currently in a Phase 1 for oncology